DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Jefferies - 3 Glen Santangelo - 3 — CNBC's Michael Bloom - 2 Truist - 2 Elanco - 1 Jeff Simmons - 1 Simmons - 1 Credelio - 1
Top related locs:
U.S buybacks Teva Monday's Xifaxan Norwich Bausch New Jersey
Top related orgs:
JPMorgan - 3 CNBC - 2 Energy - 2 pharma - 2 Merck - 1 ELAN - 1 Riney Canine Health - 1 Argus - 1

Search resuls for: "Glen Santangelo"


5 mentions found


☆ Elanco's $1.3 billion deal may give the animal health company more flexibility as product launches ramp up
  + stars: | 2024-02-06 | by ( Christina Cheddar Berk | In | ) www.cnbc.com   time to read: +6 min
Elanco Animal Health's decision to sell its aqua division will narrow its focus on pet health and livestock sustainability, as management prepares to launch several new products this year. ELAN 1Y mountain Elanco stock over the past year. One area it identified is pet health, a $15 billion market that has benefited from increasing pet ownership, especially among people who see their pets as family and value their animals' health care. 'Flexibility' to invest behind launches The product launches will also give Elanco a chance to prove itself. The pet health business is very competitive and, once approved, Zenrelia will compete directly with rival Zoetis' Apoquel.
Persons: Elanco, Jeff Simmons, Simmons, Credelio, Cornell University's Richard P, FactSet, Chris Schott, ELAN, Schott, Jefferies, Glen Santangelo, Eli Lilly, Jasper Hellweg, Hellweg, Zenrelia, Zoetis, — CNBC's Michael Bloom Organizations: Merck, CNBC, ELAN, Riney Canine Health, JPMorgan, Argus Locations: U.S
☆ Stocks making the biggest moves premarket: Coinbase, TKO Group, United Airlines, D.R. Horton and more
  + stars: | 2024-01-23 | by ( Brian Evans | ) www.cnbc.com   time to read: +5 min
The company sees earnings per share ranging between 60 and 65 cents, well below an LSEG estimate of 72 cents per share. Horton — Shares of the home construction company slipped more than 5% after first-quarter earnings per share missed Wall Street estimates. Horton earned $2.82 per share, while analysts polled by LSEG expected a profit of $2.88 per share. Analysts expected earnings of 80 cents per share, according to LSEG. Analysts expected a profit of $1.24 per share on revenue of $19.7 billion.
Persons: Truist, Enphase, Goldman Sachs, Glen Santangelo, D.R, Horton —, Horton, LSEG, Halliburton, FactSet's StreetAccount, groundings, Johnson — Johnson, Johnson, RTX, CNBC's Hakyung Kim, Samantha Subin, Jesse Pound, Lisa Kailai Han, Fred Imbert Organizations: JPMorgan, General Electric, Energy, Federal, 3M, Goldman, Teva Pharmaceutical Industries, pharma, Jefferies, Logitech —, Logitech, Wall Street, United Airlines –, United Airlines, LSEG, Boeing, Max, Barstool Sports, Netflix, Johnson, Verizon, Procter, Gamble, RTX Corporation, Wall
☆ Tuesday's analyst calls: Coinbase gets a downgrade from JPMorgan, two solar stocks are upgraded
  + stars: | 2024-01-23 | by ( Pia Singh Fred Imbert | Pia Singh | Fred Imbert | ) www.cnbc.com   time to read: +8 min
Tuesday's analyst calls include upgrades to two solar names and a downgrade to a key crypto stock. 7:05 a.m.: Citi increases Meta price target ahead of earnings Meta shares have more runway ahead, according to Citi. Analyst Kenneth Worthington downgraded the crypto exchange to underweight from neutral, reiterating his price target of $80. Analyst Jordan Levy upgraded Sunnova to buy from hold and raised his price target to $18 from $10. He upgraded Enphase Energy to buy from hold, moving his price target to $145 from $85.
Persons: Truist, Ronald Josey, Josey, — Pia Singh, TD Cowen, Jason Gabelman, Gabelman, Jefferies, Glen Santangelo, Teva, Cantor Fitzgerald, C.J, Muse, Kenneth Worthington, Worthington, Coinbase, — Fred Imbert, Jordan Levy, Levy Organizations: CNBC, Enphase Energy, Federal Reserve, JPMorgan, Citi, Meta, Exxon, Chevron, Cowen, Exxon Mobil, Teva Pharmaceuticals, Jefferies Investors, pharma, mdc, Nvidia, Energy, Sustainability Locations: buybacks, Teva, Monday's
☆ Buy this pharma stock that could more than double if it clears a legal battle, Jefferies says
  + stars: | 2023-09-20 | by ( Sarah Min | ) www.cnbc.com   time to read: +2 min
Investors should buy Bausch Health Companies as shares can more than double from here, Jefferies said. Bausch Health is embroiled in a legal battle over Xifaxan, its drug for irritable bowel syndrome with diarrhea, to prevent generics from entering the market. Bausch Health has been hoping to spin off its valuable vision care unit, Bausch + Lomb, for several years. Bausch Health shares are higher this year by more than 22%. The analyst cited other reasons why Bausch Health shares will get a boost.
Persons: Jefferies, Glen, mgt, Santangelo, Bausch, — CNBC's Michael Bloom Organizations: Health Companies, Health, Bausch Health, FDA Locations: Xifaxan, Norwich, Bausch, New Jersey
☆ Jefferies says this under-the-radar health stock can rally nearly 30%
  + stars: | 2023-02-23 | by ( Pia Singh | ) www.cnbc.com   time to read: +3 min
Jefferies reiterated HealthEquity as a buy on Wednesday, noting the company's favorable position in the health savings account market. Analyst Glen Santangelo placed a price target of $84 on the stock, suggesting shares stand to gain nearly 29% from Wednesday's close. HealthEquity shares gained 39% in 2022, but the stock is only up about 6% year to date. Although the stock has "seemingly fallen off investor's radar screens," Santangelo noted that the company is highly favored in the HSA market. "Most importantly, we believe that current consensus estimates underappreciate the impact of higher rates in [fiscal 2025 (calendar year 2024)].
0 next >>
Total: 5